Journal article
Pro-opiomelanocortin gene delivery suppresses the growth of established Lewis lung carcinoma through a melanocortin-1 receptor-independent pathway
HE Tsai, LF Liu, GJ Dusting, WT Weng, SC Chen, ML Kung, R Tee, GS Liu, MH Tai
Journal of Gene Medicine | Published : 2012
DOI: 10.1002/jgm.1625
Abstract
Background Pro-opiomelanocortin (POMC) is the precursor of several neuropeptides, such as corticotropin, melanocyte-stimulating hormone and the endogenous opioid (β-endorphin). Our previous studies have indicated that POMC gene delivery inhibited the progression and metastasis of B16-F10 melanoma via the α- melanocyte-stimulating hormone/melanortin-1 receptor (MC-1R) pathway. Methods: In the present study, the therapeutic efficacy of POMC gene therapy was evaluated in mice bearing established Lewis lung carcinoma (LLC) models both in vitro and in vivo. We also investigated the MC-1R-independent mechanism underlying POMC gene therapy. Results: We found that POMC gene delivery significantly in..
View full abstractGrants
Awarded by National Science Council, Taiwan
Awarded by Kaohsiung Veterans General Hospital, Taiwan
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
This work was supported by grants from the National Science Council, Taiwan (NSC-99-2321-B-110-005 and NSC100-2325-B-110-002), Kaohsiung Veterans General Hospital, Taiwan (VGHKS-99-036), National Sun Yat-Sen University, and the National Health and Medical Research Council of Australia (NHMRC 09007G). G.J.D. also received a Principal Research Fellowship from NHMRC and is supported by the Wicking Trust. The O'Brien Institute acknowledges the Victorian State Government's Department of Innovation, Industry and Regional Development's Operational Infrastructure Support Program. We thank Ms Cha-Hwa Ton for providing technical assistance and Dr Elsa Chan for critically reading the manuscript. The present study received no funding from industry. The authors declare that there are no conflicts of interest.